DE60236952D1 - Beschichtete teilchenförmige cefuroximeaxetil-zusammensetzungen - Google Patents

Beschichtete teilchenförmige cefuroximeaxetil-zusammensetzungen

Info

Publication number
DE60236952D1
DE60236952D1 DE60236952T DE60236952T DE60236952D1 DE 60236952 D1 DE60236952 D1 DE 60236952D1 DE 60236952 T DE60236952 T DE 60236952T DE 60236952 T DE60236952 T DE 60236952T DE 60236952 D1 DE60236952 D1 DE 60236952D1
Authority
DE
Germany
Prior art keywords
cefuroximeaxetile
compositions
coated particulate
masked
decomposing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60236952T
Other languages
German (de)
English (en)
Inventor
Matilde Ibanez Fernandez
Emilio Sanz Garriz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60236952D1 publication Critical patent/DE60236952D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
DE60236952T 2001-11-23 2002-11-21 Beschichtete teilchenförmige cefuroximeaxetil-zusammensetzungen Expired - Lifetime DE60236952D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23
PCT/EP2002/013150 WO2003043638A1 (en) 2001-11-23 2002-11-21 Coated particulate cefuroxime axetil compositions

Publications (1)

Publication Number Publication Date
DE60236952D1 true DE60236952D1 (de) 2010-08-19

Family

ID=8183502

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60236952T Expired - Lifetime DE60236952D1 (de) 2001-11-23 2002-11-21 Beschichtete teilchenförmige cefuroximeaxetil-zusammensetzungen
DE10254412A Withdrawn DE10254412A1 (de) 2001-11-23 2002-11-21 Arzneimittel
DE20218068U Expired - Lifetime DE20218068U1 (de) 2001-11-23 2002-11-21 Arzneimittel

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE10254412A Withdrawn DE10254412A1 (de) 2001-11-23 2002-11-21 Arzneimittel
DE20218068U Expired - Lifetime DE20218068U1 (de) 2001-11-23 2002-11-21 Arzneimittel

Country Status (34)

Country Link
US (1) US20030161888A1 (enExample)
EP (1) EP1446126B1 (enExample)
JP (1) JP3497503B2 (enExample)
KR (1) KR100979328B1 (enExample)
CN (1) CN1297274C (enExample)
AT (1) ATE473006T1 (enExample)
AU (2) AU2002338950A1 (enExample)
BE (2) BE1015217A5 (enExample)
BR (1) BR0204767A (enExample)
CA (1) CA2408198C (enExample)
CH (1) CH693982A5 (enExample)
CO (1) CO5580783A2 (enExample)
CY (1) CY1110778T1 (enExample)
CZ (1) CZ12993U1 (enExample)
DE (3) DE60236952D1 (enExample)
DK (1) DK1446126T3 (enExample)
ES (2) ES2201932B2 (enExample)
FR (1) FR2832635B1 (enExample)
GB (1) GB2383536B (enExample)
GR (1) GR1004522B (enExample)
HR (2) HRP20020923A2 (enExample)
HU (1) HUP0204026A3 (enExample)
IL (2) IL161972A0 (enExample)
IT (1) ITMI20022470A1 (enExample)
MX (1) MXPA02011561A (enExample)
NO (1) NO335273B1 (enExample)
NZ (1) NZ533092A (enExample)
PL (1) PL205325B1 (enExample)
PT (1) PT1446126E (enExample)
RU (1) RU2241460C2 (enExample)
SI (1) SI1446126T1 (enExample)
TR (1) TR200202559A2 (enExample)
WO (1) WO2003043638A1 (enExample)
ZA (1) ZA200209473B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1758557B1 (en) 2004-05-11 2011-07-13 Egalet Ltd. Swellable dosage form comprising gellan gum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) * 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术(石家庄)有限公司 一种微囊化头孢呋辛酯的药物组合物
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
KR101765357B1 (ko) 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
EP2566458B1 (en) 2010-05-04 2015-08-05 Mahmut Bilgic Pharmaceutical formulations compising cefuroxime axetil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2741750A1 (en) * 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
AU2012332952B2 (en) * 2011-10-31 2016-05-05 Novartis Ag Pazopanib formulation
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用
JP2023146766A (ja) * 2022-03-29 2023-10-12 味の素株式会社 造粒物およびその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
KR950703935A (ko) * 1992-11-30 1995-11-17 밋첼 아이, 커시너 맛을 차단하는 약제학적 조성물
WO1994025006A1 (en) * 1993-04-26 1994-11-10 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
US6190591B1 (en) * 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
AU5904698A (en) 1997-12-29 1999-07-19 Procter & Gamble Company, The Tablet composition
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
PT1194124E (pt) * 1999-06-11 2004-02-27 Ranbaxy Lab Ltd Composicoes de sabor mascarado

Also Published As

Publication number Publication date
WO2003043638A1 (en) 2003-05-30
NO20042620L (no) 2004-06-22
IL161972A (en) 2009-06-15
HU0204026D0 (en) 2003-01-28
HUP0204026A2 (hu) 2003-08-28
DK1446126T3 (da) 2010-10-11
MXPA02011561A (es) 2005-07-13
HUP0204026A3 (en) 2004-09-28
CY1110778T1 (el) 2015-06-10
CA2408198A1 (en) 2003-02-02
ATE473006T1 (de) 2010-07-15
GB2383536B (en) 2003-11-19
DE10254412A1 (de) 2003-06-12
KR20050044590A (ko) 2005-05-12
JP2003160493A (ja) 2003-06-03
DE20218068U1 (de) 2003-03-27
CO5580783A2 (es) 2005-11-30
CH693982A5 (de) 2004-05-28
CN1421206A (zh) 2003-06-04
CZ12993U1 (cs) 2003-02-10
CN1297274C (zh) 2007-01-31
EP1446126B1 (en) 2010-07-07
FR2832635B1 (fr) 2006-04-21
FR2832635A1 (fr) 2003-05-30
RU2241460C2 (ru) 2004-12-10
BE1015217A5 (enExample) 2004-11-09
IL161972A0 (en) 2005-11-20
EP1446126A1 (en) 2004-08-18
ES2347536T3 (es) 2010-11-02
GB0227215D0 (en) 2002-12-24
ES2201932B2 (es) 2005-03-16
TR200202559A2 (tr) 2003-06-23
PL205325B1 (pl) 2010-04-30
JP3497503B2 (ja) 2004-02-16
HRP20020924A2 (en) 2003-10-31
ZA200209473B (en) 2003-06-10
ITMI20022470A1 (it) 2003-05-24
US20030161888A1 (en) 2003-08-28
KR100979328B1 (ko) 2010-08-31
SI1446126T1 (sl) 2010-10-29
BR0204767A (pt) 2003-09-16
NZ533092A (en) 2006-02-24
AU2002302147B2 (en) 2005-01-20
GR1004522B (el) 2004-04-06
BE1014078A6 (fr) 2003-03-04
HRP20020923A2 (en) 2003-10-31
NO335273B1 (no) 2014-11-03
AU2002338950A1 (en) 2003-06-10
GB2383536A (en) 2003-07-02
PL357259A1 (en) 2003-06-02
PT1446126E (pt) 2010-09-24
GR20020100506A (el) 2003-07-16
CA2408198C (en) 2004-03-09
ES2201932A1 (es) 2004-03-16

Similar Documents

Publication Publication Date Title
ATE473006T1 (de) Beschichtete teilchenförmige cefuroximeaxetil- zusammensetzungen
JP2003524592A5 (enExample)
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
NO20004190L (no) Oralt administrerbar galenisk form med umiddelbar frigivelse og langvarig frigivelse som omfatter et absorpsjonsfremmende middel, og anvendelse av dette absorpsjonsfremmende middel
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
AU2003293207A1 (en) Density-controlled particulate suspensions for foodstuff, cosmetic, pharmaceutical and other uses
EP1258200A3 (de) Verwendung von Hydroxyflavanone zur Maskierung des bitteren Geschmacks, und Lebensmittel und pharmazeutische Zusammensetzungen enthaltend eine wirksame Menge dieser Hydroxyflavone
PT1094788E (pt) Dissimulacao do sabor com croscarmelose
RU2002131380A (ru) Фармацевтические композиции
AU3951595A (en) Coating for taste masking orally administered bitter drugs
GEP20063821B (en) Orodispersible pharmaceutical composition comprising perindopril
WO2004009085A3 (en) Taste masked sumatriptan tablets and processes for their preparation
GEP20063820B (en) Orodispersible pharmaceutical composition comprising ivabradine
DE69813846T2 (de) Geschmacksmaskierung schlecht schmeckender formulierungen
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application
WO1998036732A3 (de) Kombinationspräparat für oral applizierbare antibiotika
MXPA03001952A (es) Sistemas saborizantes para composiciones farmaceuticas y metodos para hacer dichas composiciones.
CA2312072A1 (en) Oil-free popped wild rice cereal
WO2001007019A3 (en) Use of n-acetyl-cysteine in the treatment of allergic pathologies of the respiratory tract
WO2002036774A3 (de) Derivate des humanen makrophagen migrations-inhibitions-faktors (mif) und deren verwendung in arzneimittelzubereitung und in screeningverfahren zur identifizierung von analoga, agonisten und antagonisten
EA200400885A1 (ru) Диспергируемая во рту фармацевтическая композиция пирибедила
BR9804052A (pt) Suspensão oral de praziquantel.
WO2003013471A3 (en) Pharmaceutical enteric coated composition comprising chitosan
RU2002120354A (ru) Биологически активная добавка "мумивит с витамином "с"